GlassScriptPhysician profile
Amir Neshatfar
NPI 1821550831
$996.55
in general payments reported to CMS, 2019-2025
13 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $46.14 · 2024: $753 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $589.61 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $93.18 | 2024-2025 | |
| Ucb, INC. | $54.93 | 2024 | Briviact, Nayzilam |
| Pfizer INC. | $52.70 | 2023-2025 | |
| Emd Serono, INC. | $38.03 | 2024-2025 | |
| Lilly USA, LLC | $30.04 | 2024-2025 | Emgality |
| Novartis Pharmaceuticals Corporation | $25.84 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $24.70 | 2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $23.60 | 2025 | Xeomin |
| Axsome Therapeutics, INC. | $17.94 | 2024 | Sunosi |
| Sumitomo Pharma America, INC. | $16.82 | 2023 | Aptiom |
| Tg Therapeutics, INC. | $15.89 | 2025 | |
| Horizon Therapeutics Plc | $13.27 | 2023 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Neshatfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.